High Dose Thera CoQ10 (Coenzyme Q10)
A Hearth Healthy Supplement with 120 mg per Softgel Capsule
| $29.99 | 50 Count Bottle VP4222K | Retails for $39.90 | |
| $54.99 | 100 Count Bottle VP4222R | Retails for $75.90 | |
| $549.99 | 12 Bottles 100 Count Each | Retail Value $910.80 | |
|
Display An Attractive 12 Bottle Case On Your Counter for Patient/Client Convenience. Additional Wholesale Discounts Available |
|||
Take Advantage Our Recent Huge Price Reduction! The 100 count bottle used to sell for over $100
Coenzyme Q10 acts as a powerful antioxidant that boosts the heart's ability to endure stress. Thera CoQ10 supplies 120 mg of potent coenzyme Q10, a therapeutic dosage for those individuals who rely upon this energy producing, cardio protective nutrient.
Each capsule is fortified with 30iu of essential Vitamin E (from mixed tocopherols) making it additionally valuable for supplying oxygen to the heart and other muscle tissue throughout the body.
Essential for energy production and the health of all of the body's cells, tissues and organs, CoQ10 is one of the most important nutrients to include in your daily regimen...
Thera CoQ10 is the highest potency Coenzyme Q10 available.
No caffeine, corn, gluten, milk or egg derivatives, slat, sodium, starch, sugar, wheat or yeast. No artificial flavorings or preservatives.
Coenzyme Q10 was discovered in 1957. Interest in coenzyme Q10 as a potential treatment for cancer started in 1961, when it was found to be deficient in the blood of cancer patients. Low blood levels of coenzyme Q10 have been found in patients with myeloma, lymphoma, and cancers of the breast, lung, prostate, pancreas, colon, kidney, and head and neck.
Studies show how coenzyme Q10 works in the body to produce energy and act as an antioxidant. Some studies suggest that coenzyme Q10 stimulates the immune system and increases resistance to disease. Researchers theorize that coenzyme Q10 may be useful in adjuvant therapy for cancer. (Adjuvant therapy is treatment given following the primary treatment to enhance the effectiveness of the primary treatment.)
Find CoQ10 Supplements at a Featured Merchant (below)
Erectile Dysfunction May Signal Serious Heart Problems
Erectile dysfunction (ED) is often a matter of the heart, but new research shows that more than romance is at stake. Two new studies of men with type 2 Diabetes found that erectile dysfunction (ED) was a major early warning sign for serious heart disease, including heart attack and death.
One of the studies also showed that cholesterol- lowering medications (statins) could cut the risk of heart problems by about one-third--and suggested that other compounds in the same drug category might offer protection. The research, which was published in most recent issue of the Journal of the American College of Cardiology (JACC), underscores the importance of encouraging men to report ED to their physicians, and of focusing treatment not only on overcoming sexual dysfunction but also on improving overall cardiovascular health. The development of erectile dysfunction should alert both patients and healthcare providers to the potential future risk of coronary heart disease.
Other risk factors include: poor blood glucose control, high blood pressure, high cholesterol levels, smoking and obesity. Diabetes, erectile dysfunction and heart disease share a critical, dangerous link... damage to the blood vessels by high blood sugar levels. The same process that impedes the extra blood flow needed to maintain an erection can have serious consequences in the heart. When the smoothness and reactivity of the blood vessel are damaged, this process encourages local inflammation on the inner surface of the blood vessels and the deposition of cholesterol, resulting in formation of dangerous clots and atherosclerosis. Therefore, there is a high risk of blockage of blood vessels in the heart, which can lead to a heart attack.
Men typically show signs of ED more than three years before the onset of symptoms of coronary heart disease. In one study of diabetic men, symptoms of ED always preceded coronary symptoms.
Men who had ED at the beginning of the study were far more likely to develop one of the signs of coronary heart disease--or a "CHD event"--than were men who initially did not have ED. Statistical analysis showed that out of every 1,000 Diabetic men with ED, 19.7 could be expected to experience a CHD event each year, as compared to only 9.5 of 1,000 diabetic men without ED.
The research team then performed an analysis that included many different characteristics that, like erectile dysfunction, were associated with the development of CHD, including age, high blood pressure, the need for cholesterol-or blood- pressure-lowering medications, the duration of diabetes, and damage to the kidneys or the eyes as a result of diabetes. Even when these characteristics were taken into account, ED was found to be an independent early warning sign of coronary heart disease. In fact, ED signaled a 58 percent increase in the risk of CHD. Only spillage of large amounts of protein in the urine--a sign of extensive kidney damage--was a stronger warning sign, doubling the risk of heart disease.
Another study, conducted by researchers from four medical centers in Italy, focused on 291 men who not only had type 2 Diabetes but also silent CHD (Coronary Heart Disease) discovered by stress testing and confirmed by x-ray angiography. Of these, 118 had ED at the beginning of the study. They found that patients who had ED at the beginning of the study were twice as likely to suffer a major adverse cardiac event when compared to those without ED. Thus, ED remained a significant risk factor for developing heart disease after controlling for other cardiovascular risk factors.
"Men should know that ED is a true harbinger of atherosclerotic coronary heart disease," he said. Dr. Kloner, who wrote an editorial about the new studies in the same issue of JACC, also noted that not only have statins been shown to reduce the risk of cardiovascular illness in diabetic patients, controlling blood pressure and other risk factors is also critical. "In diabetic patients, it is important to not only control the blood sugar level, but also to keep blood pressure below 130/80 mmHg and reduce 'bad' (low-density-lipoprotein, or LDL) cholesterol to less than 100 mg/dL. If a patient smokes, a smoking cessation program is crucial," Dr. Kloner said.
Improvements in the control of blood sugar and other cardiovascular risk factors reduce the likelihood of developing erectile dysfunction or suffering a heart attack or other serious heart disease. Patients who have ED in addition to diabetes-related eye problems and kidney problems at higher risk for death or cardiovascular disease. All are relevant to those who suffer from Diabetes. Proper information about these conditions and aggressive treatment of critical warning signs with appropriate medications, healthier daily dietary habits, increased physical activity and proper nutritional intake will help patients to focus on improving their own health.
Coenzyme Q10 (CoQ10) is known as "Ubiquinone" and is present in almost every cell in the body. It is a naturally occurring cofactor in the electron transport chain, the biochemical pathway in cellular respiration from which most of the body's energy at a fundamental cellular level (Kreb cycle) are derived. It is essential for the health of all the body's cells, tissues and organs.
Clinical studies have shown that coenzyme Q10 aids circulation, supports the immune system, increases tissue oxygenation, helps promote weight-loss and has valuable anti-aging properties. Coenzyme Q10 also has beneficial protective antioxidant benefits. Deficiences have been linked to higher incidence of diabetes, cardiovascular disease, periodontal problems and muscular dystrophy.
Benefit Of Aspirin For Healthy People Is Uncertain
An important new study has shown that, while taking aspirin is beneficial in preventing heart attacks and strokes among people with established cardiovascular disease (secondary prevention), its benefits don't clearly outweigh the risks in healthy people (primary prevention).
Researchers at the Clinical Trial Service Unit at the University of Oxford analyzed data from a number of primary and secondary prevention trials that had compared long-term aspirin use against controls. The findings are published in The Lancet.
In the primary prevention trials, aspirin reduced the risk of a non-fatal heart attack by about 20%. This corresponds to five fewer such episodes each year for every 10,000 people treated. This is offset by a comparable increase in bleeds with long-term aspirin use. One extra stroke is caused by bleeding and three extra gastrointestinal bleeds occur each year per 10,000 treated.
In the secondary prevention studies, aspirin reduced the risk of a serious vascular event (a heart attack, stroke or cardiovascular death) by about a fifth. But the risk of an event is much higher among people with established cardiovascular disease, so that there were 150 fewer such events each year for every 10,000 patients treated. This large benefit greatly exceeds the risk of bleeding.
In both sets of trials, the risk of a serious vascular event was reduced to a similar degree in both men and women. Previous reviews of primary prevention trials have led to guidelines recommending that aspirin be used widely among healthy people who are more at risk of coronary heart disease, having raised blood cholesterol or blood pressure for example.
But the new analysis demonstrate that many people with above average risk of coronary heart disease are also at above average risk of suffering a bleed, so this method of selecting whom to treat may not be appropriate.
The lead researcher explains... "The primary prevention trials were completed some years ago, when modern drugs such as statins were not widely available. Today, primary prevention with statins and other drugs can safely half the risk of heart attacks and strokes."
It is important to recognize...When aspirin is added to such drugs, the further reduction in serious vascular events is only about half as large as when it is used alone, but the bleeding risks will remain about the same. This has important implications when judging the likely effects of aspirin in practice.
The researchers conclude: "Aspirin is of clear benefit for people who already have cardiovascular disease, but the latest research does not seem to justify general guidelines advocating the routine use of aspirin in all healthy individuals above a moderate level of risk for coronary heart disease."
Adapted from materials provided by University of Oxford.
